EHA 2022
EUROPEAN HEMATOLOGY ASSOCIATION (EHA) 2022 CONGRESS
JUNE 9-12 | VIRTUAL
Acalabrutinib maintains PFS benefit in rrCLL: A 4-year follow-up of the ASCEND trial
ARI0002h, an academic BCMA-directed CAR T-cell therapy, improves ORR IN rrMM patients
FD ibrutinib + venetoclax continues to demonstrate benefit in CLL/SLL: 3-year follow-up of the phase 2 CAPTIVATE study
10-day decitabine demonstrates similar OS to conventional 3+7 chemotherapy for HSCT in AML patients
Venetoclax-obinutuzumab +/- ibrutinib improve PFS in CLL:The GAIA/CLL13 trial
Quizartinib + intensive induction and consolidation therapy followed by single-agent continuation improves OS in patients with newly diagnosed FLT3-ITD-positive AML
Zanubrutinib and obinutuzumab combination improves ORR IN rrFL patients: the phase 2 ROSEWOOD trial